Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-108 and toripalimab in metastatic triple-negative breast cancer
NCT06387628Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2024
- Primary completion
- Apr 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of LM-108 in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Jul 2024; status: recruiting.
02
Drugs
LM-108
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06387628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06387628.